Literature DB >> 4402925

Theory of antimotion sickness drug mechanisms.

C D Wood, A Graybiel.   

Abstract

Mesh:

Substances:

Year:  1972        PMID: 4402925

Source DB:  PubMed          Journal:  Aerosp Med        ISSN: 0001-9402


× No keyword cloud information.
  8 in total

Review 1.  Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.

Authors:  Zohar Nachum; Avi Shupak; Carlos R Gordon
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) upon psychological performance.

Authors:  A C Parrott
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  The Impact of Oral Promethazine on Human Whole-Body Motion Perceptual Thresholds.

Authors:  Ana Diaz-Artiles; Adrian J Priesol; Torin K Clark; David P Sherwood; Charles M Oman; Laurence R Young; Faisal Karmali
Journal:  J Assoc Res Otolaryngol       Date:  2017-04-24

4.  Interaction between hyperbaric air and d-amphetamine effects on performance.

Authors:  J R Thomas
Journal:  Psychopharmacology (Berl)       Date:  1976-07-09       Impact factor: 4.530

5.  Central and peripheral effects of arecoline in patients with autonomic failure.

Authors:  R J Polinsky; R T Brown; M T Curras; S M Baser; C E Baucom; D R Hooper; A M Marini
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-09       Impact factor: 10.154

Review 6.  Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  S P Clissold; R C Heel
Journal:  Drugs       Date:  1985-03       Impact factor: 9.546

7.  Antiemetic efficacy of promethazine on xylazine-induced emesis in cats.

Authors:  Saeed Kolahian; Seyed Hosein Jarolmasjed
Journal:  Can Vet J       Date:  2012-02       Impact factor: 1.008

Review 8.  Do conditioned taste aversions result from activation of emetic mechanisms?

Authors:  V L Grant
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.